Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 609

1.

Reconstruction with scrotal flap for extramammary Paget's disease of the groin, penis, and scrotum: a single-institution case series.

Tsutsui K, Namikawa K, Takahashi A, Yamazaki N.

Int J Dermatol. 2019 Nov 14. doi: 10.1111/ijd.14723. [Epub ahead of print] No abstract available.

PMID:
31724734
2.

[Segmentectomy for Congenital Left Upper Lobar Bronchial Atresia].

Kou Y, Tanaka H, Yamazaki N, Watanabe H, Sonobe M.

Kyobu Geka. 2019 Nov;72(12):1001-1004. Japanese.

PMID:
31701911
3.

Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.

Muto Y, Namikawa K, Fujiwara Y, Mori T, Nakano E, Takahashi A, Yamazaki N.

J Dermatol. 2019 Oct 31. doi: 10.1111/1346-8138.15140. [Epub ahead of print] No abstract available.

PMID:
31674068
4.

Aqueous Lubrication with the Molecularly Confined Films of Silicone-Based Amphiphilic Block Copolymer Aggregates.

Miyamoto T, Yamazaki N, Watanabe S, Yamada S.

Langmuir. 2019 Dec 3;35(48):15784-15794. doi: 10.1021/acs.langmuir.9b03212. Epub 2019 Nov 8.

PMID:
31656076
5.

Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol).

Tanaka K, Nakamura Y, Mizutani T, Shibata T, Tsutsumida A, Fukuda H, Matsushita S, Aoki M, Namikawa K, Ohe S, Fukushima S, Yamazaki N; Dermatologic Oncology Group of the Japan Clinical Oncology Group.

BMC Cancer. 2019 Oct 25;19(1):1002. doi: 10.1186/s12885-019-6248-2.

6.

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.

Yokota K, Uchi H, Uhara H, Yoshikawa S, Takenouchi T, Inozume T, Ozawa K, Ihn H, Fujisawa Y, Qureshi A, de Pril V, Otsuka Y, Weber J, Yamazaki N.

J Dermatol. 2019 Dec;46(12):1197-1201. doi: 10.1111/1346-8138.15103. Epub 2019 Oct 22.

PMID:
31638282
7.

Treatment strategy for pediatric giant mucinous cystadenoma: A case report.

Watanabe S, Nagashima S, Onagi C, Yamazaki N, Shimada S, Sakai M, Yanai S, Haga Y, Ohara A, Kuroiwa M.

Pediatr Rep. 2019 Sep 24;11(3):8190. doi: 10.4081/pr.2019.8190. eCollection 2019 Sep 24.

8.

Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma.

Tsutsumida A, Fukushima S, Yokota K, Yoshikawa S, Yamasaki O, Tanemura A, Okuyama R, Uhara H, Muto Y, Miyashita A, Akiyama M, Kaji T, Koga H, Kato J, Katayama T, Itakura E, Yamazaki N, Kiyohara Y.

J Dermatol. 2019 Nov;46(11):947-955. doi: 10.1111/1346-8138.15073. Epub 2019 Sep 17.

PMID:
31531895
9.

[Ectopic Hilar Thymoma Associated with Morvan Syndrome after Extended Thymectomy for Myasthenia Gravis].

Shimazu Y, Tanaka H, Watanabe H, Yamazaki N, Nakade M.

Kyobu Geka. 2019 Sep;72(9):660-663. Japanese.

PMID:
31506405
10.

Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study.

Kinoshita T, Nakayama T, Fukuma E, Inokuchi M, Ishiguro H, Ogo E, Kikuchi M, Jinno H, Yamazaki N, Toi M.

Front Oncol. 2019 Aug 6;9:733. doi: 10.3389/fonc.2019.00733. eCollection 2019.

11.

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2019 Sep;119:97-106. doi: 10.1016/j.ejca.2019.07.016. Epub 2019 Aug 19.

12.

Advanced extramammary Paget disease treated with neoadjuvant chemotherapy: A report of two cases.

Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.

Australas J Dermatol. 2019 Jul 18. doi: 10.1111/ajd.13119. [Epub ahead of print] No abstract available.

PMID:
31318039
13.

Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.

Sekine S, Kiyono T, Ryo E, Ogawa R, Wakai S, Ichikawa H, Suzuki K, Arai S, Tsuta K, Ishida M, Sasajima Y, Goshima N, Yamazaki N, Mori T.

J Clin Invest. 2019 May 30;130:3827-3832. doi: 10.1172/JCI126185.

14.

Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.

Namikawa K, Takahashi A, Mori T, Tsutsumida A, Suzuki S, Motoi N, Jinnai S, Kage Y, Mizuta H, Muto Y, Nakano E, Yamazaki N.

Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000617. [Epub ahead of print]

PMID:
31095037
15.

Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.

Baba T, Sakai F, Kato T, Kusumoto M, Kenmotsu H, Sugiura H, Tominaga J, Oikado K, Sata M, Endo M, Yanagawa N, Sasaki S, Iwasawa T, Saito Y, Fujiwara Y, Ohe Y, Yamazaki N, Sakamoto T, Koshiba T, Kuwano K.

Future Oncol. 2019 Jun;15(16):1911-1920. doi: 10.2217/fon-2019-0102. Epub 2019 Apr 25.

16.

Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.

Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, Uchi H, Ihn H, Hatsumichi M, Minami H.

Cancer Sci. 2019 Jun;110(6):1995-2003. doi: 10.1111/cas.14015. Epub 2019 May 23.

17.

Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.

Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.

J Dermatol. 2019 Jun;46(6):498-506. doi: 10.1111/1346-8138.14865. Epub 2019 Apr 4.

PMID:
30945333
18.

Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.

Ishida H, Shimizu Y, Sakaguchi H, Nitanda H, Kaneko K, Yamazaki N, Yanagihara A, Taguchi R, Sakai F, Yasuda M, Kobayashi K.

Lung Cancer. 2019 Mar;129:16-21. doi: 10.1016/j.lungcan.2018.12.020. Epub 2018 Dec 19.

19.

Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings.

Yamazaki N, Kosuga M, Kida K, Takei G, Fukuhara Y, Matsumoto H, Senda M, Honda A, Ishiguro A, Koike T, Yabe H, Okuyama T.

Brain Dev. 2019 Jun;41(6):546-550. doi: 10.1016/j.braindev.2019.01.008. Epub 2019 Feb 10.

PMID:
30755342
20.

Targeted Therapy and Immunotherapy for Melanoma in Japan.

Namikawa K, Yamazaki N.

Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8. Review.

21.

Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.

Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T, Yamazaki N, Takikawa H, Morimoto T, Chosa M, Sunaya T, Hamada Y, Muro K, Sugihara K.

Oncologist. 2019 Jul;24(7):e450-e457. doi: 10.1634/theoncologist.2018-0377. Epub 2019 Jan 3.

PMID:
30606885
22.

Frequent mutations of genes encoding vacuolar H+ -ATPase components in granular cell tumors.

Sekimizu M, Yoshida A, Mitani S, Asano N, Hirata M, Kubo T, Yamazaki F, Sakamoto H, Kato M, Makise N, Mori T, Yamazaki N, Sekine S, Oda I, Watanabe SI, Hiraga H, Yonemoto T, Kawamoto T, Naka N, Funauchi Y, Nishida Y, Honoki K, Kawano H, Tsuchiya H, Kunisada T, Matsuda K, Inagaki K, Kawai A, Ichikawa H.

Genes Chromosomes Cancer. 2019 Jun;58(6):373-380. doi: 10.1002/gcc.22727. Epub 2019 Jan 21.

PMID:
30597645
23.

Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.

Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Asada S, Namba Y, Yamazaki N.

Eur J Cancer. 2018 Dec;105:114-126. doi: 10.1016/j.ejca.2018.09.025. Epub 2018 Nov 15.

24.

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.

Kikuchi K, Nozawa K, Yamazaki N, Nakai Y, Higashiyama A, Asano M, Fujiwara Y, Kanda S, Ohe Y, Takashima A, Boku N, Inoue A, Takahashi M, Mori T, Taguchi O, Inoue Y, Mizutani H.

J Dermatol. 2019 Jan;46(1):18-25. doi: 10.1111/1346-8138.14691. Epub 2018 Nov 7.

PMID:
30402978
25.

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab.

Watanabe R, Nakano E, Kawazoe A, Kuboki Y, Bando H, Shitara K, Takahashi A, Tsutsumida A, Nishizawa A, Yamazaki N.

J Dermatol. 2019 May;46(5):e178-e180. doi: 10.1111/1346-8138.14693. Epub 2018 Oct 31. No abstract available.

PMID:
30379358
26.

Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data.

Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Kobayashi Y, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y.

Oncologist. 2019 Feb;24(2):266-272. doi: 10.1634/theoncologist.2017-0511. Epub 2018 Sep 25.

PMID:
30254188
27.

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.

Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y.

Cancer Sci. 2018 Nov;109(11):3583-3590. doi: 10.1111/cas.13800. Epub 2018 Oct 13.

28.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
29.

Pre-emptive skin treatments to prevent skin toxicity caused by anti-EGFR antibody: the real-world evidence in Japan.

Yamazaki N, Oomuku Y, Mishiro I, Soeda J.

Future Oncol. 2018 Dec;14(30):3163-3174. doi: 10.2217/fon-2018-0379. Epub 2018 Sep 14.

30.

Use of modified U1 small nuclear RNA for rescue from exon 7 skipping caused by 5'-splice site mutation of human cathepsin A gene.

Yamazaki N, Kanazawa K, Kimura M, Ike H, Shinomiya M, Tanaka S, Shinohara Y, Minakawa N, Itoh K, Takiguchi Y.

Gene. 2018 Nov 30;677:41-48. doi: 10.1016/j.gene.2018.07.030. Epub 2018 Jul 24.

PMID:
30010039
31.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
32.

Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face -a retrospective study of 38 untreated cases in the Japanese population.

Oashi K, Namikawa K, Tsutsumida A, Takahashi A, Itami J, Igaki H, Inaba K, Yamazaki N.

Eur J Surg Oncol. 2018 Jun;44(6):823-829. doi: 10.1016/j.ejso.2018.02.246. Epub 2018 Mar 6.

PMID:
29555155
33.

Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.

Takahashi A, Tsutsumida A, Namikawa K, Yamazaki N.

Melanoma Res. 2018 Apr;28(2):159-160. doi: 10.1097/CMR.0000000000000418. No abstract available.

PMID:
29485550
34.

Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance.

Kiyohara Y, Uhara H, Ito Y, Matsumoto N, Tsuchida T, Yamazaki N.

J Dermatol. 2018 Apr;45(4):408-415. doi: 10.1111/1346-8138.14227. Epub 2018 Feb 20.

PMID:
29464755
35.

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, Yoshikawa S, Fujiwara Y, Kondo S, Mukaiyama A, Zhang F, Kiyohara Y.

J Dermatol. 2018 Apr;45(4):397-407. doi: 10.1111/1346-8138.14210. Epub 2018 Feb 5.

36.

Euglena gracilis Z and its carbohydrate storage substance relieve arthritis symptoms by modulating Th17 immunity.

Suzuki K, Nakashima A, Igarashi M, Saito K, Konno M, Yamazaki N, Takimoto H.

PLoS One. 2018 Feb 1;13(2):e0191462. doi: 10.1371/journal.pone.0191462. eCollection 2018.

37.

Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.

Muto Y, Ng W, Namikawa K, Takahashi A, Tsutsumida A, Nishida M, Yamazaki N.

Melanoma Res. 2018 Apr;28(2):151-154. doi: 10.1097/CMR.0000000000000424.

PMID:
29356791
38.

Nail apparatus melanoma in a Japanese population: a comparative study of surgical procedures and prognoses in a large series of 151 cases.

Ogata D, Uhara H, Tsutsumida A, Yamazaki N, Mochida K, Amano M, Yoshikawa S, Kiyohara Y, Tsuchida T.

Eur J Dermatol. 2017 Dec 1;27(6):620-626. doi: 10.1684/ejd.2017.3133.

PMID:
29165298
39.

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).

Namikawa K, Tsutsumida A, Mizutani T, Shibata T, Takenouchi T, Yoshikawa S, Kiyohara Y, Uchi H, Furue M, Ogata D, Tsuchida T, Yamazaki N.

Jpn J Clin Oncol. 2017 Jul 1;47(7):664-667. doi: 10.1093/jjco/hyx063.

40.

A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.

Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, Mashima R, Kosuga M, Okuyama T.

Mol Genet Metab Rep. 2017 Oct 31;14:3-9. doi: 10.1016/j.ymgmr.2017.10.009. eCollection 2018 Mar.

41.

Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis.

Baumer Y, McCurdy S, Weatherby TM, Mehta NN, Halbherr S, Halbherr P, Yamazaki N, Boisvert WA.

Nat Commun. 2017 Oct 24;8(1):1129. doi: 10.1038/s41467-017-01186-z.

42.

Oral administration of Euglena gracilis Z and its carbohydrate storage substance provides survival protection against influenza virus infection in mice.

Nakashima A, Suzuki K, Asayama Y, Konno M, Saito K, Yamazaki N, Takimoto H.

Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):379-383. doi: 10.1016/j.bbrc.2017.09.167. Epub 2017 Sep 30.

43.

Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer.

Mita K, Ito H, Katsube T, Tsuboi A, Yamazaki N, Asakawa H, Hayashi T, Fujino K.

J Gastrointest Surg. 2017 Dec;21(12):1993-1999. doi: 10.1007/s11605-017-3559-y. Epub 2017 Sep 22.

PMID:
28940122
44.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

45.

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.

Fujiwara Y, Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Mukaiyama A, Zhang F, Tamura T.

Invest New Drugs. 2018 Apr;36(2):259-268. doi: 10.1007/s10637-017-0502-8. Epub 2017 Sep 7.

PMID:
28879519
46.

A Symptomatic Case of Adenomatous Ductal Proliferation/Hyperplasia with a Large Cystic Lesion.

Seki N, Yamazaki N, Ikeda T, Hadara H, Himi T.

Case Rep Oncol. 2017 Jul 27;10(2):676-682. doi: 10.1159/000478997. eCollection 2017 May-Aug.

47.

Survivin: A novel marker and potential therapeutic target for human angiosarcoma.

Tsuneki M, Kinjo T, Mori T, Yoshida A, Kuyama K, Ohira A, Miyagi T, Takahashi K, Kawai A, Chuman H, Yamazaki N, Masuzawa M, Arakawa H.

Cancer Sci. 2017 Nov;108(11):2295-2305. doi: 10.1111/cas.13379. Epub 2017 Sep 15.

48.

Carboxylated phytosterol derivative-introduced liposomes for skin environment-responsive transdermal drug delivery system.

Yamazaki N, Yamakawa S, Sugimoto T, Yoshizaki Y, Teranishi R, Hayashi T, Kotaka A, Shinde C, Kumei T, Sumida Y, Shimizu T, Ohashi Y, Yuba E, Harada A, Kono K.

J Liposome Res. 2018 Dec;28(4):275-284. doi: 10.1080/08982104.2017.1369995. Epub 2017 Sep 5.

PMID:
28826275
49.

Simple and efficient knockdown of His-tagged proteins by ternary molecules consisting of a His-tag ligand, a ubiquitin ligase ligand, and a cell-penetrating peptide.

Hattori T, Okitsu K, Yamazaki N, Ohoka N, Shibata N, Misawa T, Kurihara M, Demizu Y, Naito M.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4478-4481. doi: 10.1016/j.bmcl.2017.08.001. Epub 2017 Aug 2.

PMID:
28807436
50.

Rapidly developed BRAF inhibitor-induced verrucous keratosis.

Nakamura Y, Mori T, Takae Y, Tsutsumida A, Takahashi A, Namikawa K, Hirai I, Yamazaki N.

J Dermatol. 2017 Nov;44(11):e274-e275. doi: 10.1111/1346-8138.13962. Epub 2017 Jul 22. No abstract available.

PMID:
28734005

Supplemental Content

Loading ...
Support Center